Changes of cardiac function in diabetic dogs

Vichit, Pleansaung; Rungsipipat, Anudep; Surachetpong, Sirilak Disatian

doi:10.1016/j.jvc.2018.08.001

Cited by 3 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the type of tumor in this study was different from the previously reported tumor, it was considered that the results of galectin-3 levels in dogs with neoplasia would be different from previous results. In cardiac diseases, galectin-3 has been widely known as cardiac biomarkers reflecting cardiac fibrosis in both humans (1) and dogs (39), and the results of this study supported the previous results that dogs affected by heart diseases had significantly higher galectin-3 levels than healthy dogs. Cardiac fibrosis refers to several changes in the structure of interstitial collagen in the myocardium caused by a variety of cardiomyopathies (40).…”

Section: Discussionsupporting

confidence: 90%

Circulating Galectin-3 Evaluation in Dogs With Cardiac and Non-cardiac Diseases

Lee

Kang

et al. 2021

Front. Vet. Sci.

View full text Add to dashboard Cite

Galectin-3 is involved in important biological functions such as fibrogenesis and inflammation. Notably, it is associated with various diseases and plays a major role in cardiac inflammation and fibrosis. Although heart diseases are relatively common in dogs, a few studies have analyzed the circulating galectin-3 concentration in dogs with various heart diseases, including myxomatous mitral valve disease, patent ductus arteriosus, and pulmonic stenosis. The aims of the present study were to evaluate the effect of heart disease on circulating galectin-3 levels in dogs, and also to evaluate the correlation between galectin-3 concentration and conventional echocardiographic indices along with N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration in dogs with heart diseases. The medical records and archived serum samples of 107 dogs were evaluated retrospectively. In total, 107 dogs were classified into healthy dogs (n = 8), cardiac disease (n = 26), and non-cardiac disease groups (n = 73). The circulatory galectin-3 levels were analyzed using a commercially available canine-specific galectin-3 enzyme-linked immunosorbent assay kit. This study demonstrated that dogs with heart, endocrine, and dermatologic diseases had significantly higher galectin-3 levels than healthy dogs (p = 0.009, p = 0.007, and p = 0.026, respectively). Among dogs with heart diseases, dogs with concentric cardiomyopathy had significantly increased circulatory galectin-3 levels compared with healthy dogs (p = 0.028). E′/A′ had a positive association with galectin-3 levels among conventional echocardiographic indices. Moreover, the galectin-3 concentration could predict diastolic dysfunction. In dogs with myxomatous mitral valve disease, a significantly positive correlation was revealed between galectin-3 levels and NT-proBNP levels (p = 0.007). Overall, this study demonstrates that circulatory galectin-3 levels increase in dogs with heart, endocrine, and dermatologic diseases. Moreover, this study demonstrates that galectin-3 concentration could be helpful to evaluate cardiac remodeling and diastolic function. Further large-scale research is required to evaluate the role of circulating galectin-3 in dogs with heart diseases.

show abstract

Section: Discussionsupporting

confidence: 90%

Circulating Galectin-3 Evaluation in Dogs With Cardiac and Non-cardiac Diseases

Lee

Kang

et al. 2021

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…29 Increased Gal-3 concentrations are present in diseases with myocardial fibrosis, 17,29 and often are found in humans with poor outcomes. 17,[30][31][32][33] Although Gal-3 has been evaluated in dogs, 34,35 a thorough evaluation of Gal-3 has not been performed in dogs with PS. Studies evaluating RV systolic function have been performed in dogs with PS, 15,36 but evaluation of RV diastolic function is rare in dogs.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of right ventricular diastolic function, systolic function, and circulating galectin‐3 concentrations in dogs with pulmonary stenosis

Winter,

Maneval,

Ferrel

et al. 2023

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundCardiovascular diseases with increased right ventricular (RV) afterload induce RV diastolic and systolic dysfunction, and myocardial fibrosis in humans. Studies in dogs with pulmonary stenosis (PS) evaluating RV diastolic function and markers of myocardial fibrosis are lacking.Hypothesis/ObjectivesDogs with PS have echocardiographic evidence of RV diastolic and systolic dysfunction and increased serum concentrations of galectin‐3 (Gal‐3), a surrogate biomarker for myocardial fibrosis.AnimalsForty client‐owned dogs (10 controls, 30 with PS).MethodsProspective study. All dogs had systemic blood pressure measurement, serum biochemical analysis, echocardiography, and measurement of serum Gal‐3 concentration performed.ResultsVariables of RV diastolic function were obtained in 39/40 dogs. Trans‐tricuspid flow velocity in early diastole to trans‐tricuspid flow velocity in late diastole ratios (RV E/A) were lower (P < .001) in dogs with PS (median, 0.94; range, 0.62‐2.04) compared to controls (1.78; 1.17‐2.35). Trans‐tricuspid flow velocity in early diastole to tricuspid annular myocardial velocity in early diastole ratios (RV E/e′) were higher (P < .001) in dogs with PS (11.55; 4.69‐28) compared to control (6.21; 5.16‐7.21). Variables of RV systolic function were lower in dogs with PS (P = <.001). Serum Gal‐3 concentration was higher (P = .002) in dogs with PS (285.1 pg/mL; 94.71‐406.97) compared to control dogs (162.83 pg/mL; 52.3‐232.82).Conclusions and Clinical ImportanceDogs with PS have RV diastolic and systolic dysfunction, and increased Gal‐3 concentrations. These findings suggest the presence of RV myocardial fibrosis in dogs with PS, which could impact clinical management.

show abstract